Welcome to our dedicated page for Opgen news (Ticker: OPGN), a resource for investors and traders seeking the latest updates and insights on Opgen stock.
OpGen, Inc. (NASDAQ: OPGN) delivers cutting-edge molecular diagnostics and bioinformatics solutions to combat infectious diseases through its Acuitas Lighthouse® knowledgebase and CLIA-certified laboratory services. This dedicated news hub provides investors and healthcare professionals with essential updates about the company's advancements in precision medicine.
Access timely information on FDA-cleared diagnostic developments, clinical trial milestones, and strategic partnerships. Our curated collection includes earnings reports, operational updates, and analyses of OpGen's antimicrobial resistance detection technologies. All content is verified through primary sources to ensure accuracy.
Key focus areas span rapid pathogen identification systems, genomic sequencing innovations, and infection control solutions for hospital networks. Regular updates reflect OpGen's commitment to transforming microbial analysis through its unique integration of laboratory science and computational bioinformatics.
Bookmark this page to stay informed about critical developments affecting OPGN's market position and technological roadmap. Check regularly for authoritative insights into one of molecular diagnostics' most innovative players.
OpGen has received a notice from Nasdaq for not filing its quarterly report on Form 10-Q for the period ending March 31, 2024. This adds to OpGen's prior issues of not filing its annual report for 2023 on time and failing to maintain a minimum bid price of $1.00 per share. The Nasdaq Hearings Panel has given OpGen until June 3, 2024, to resolve these compliance issues. While the company is taking steps to address the concerns, the notice currently has no immediate impact on the trading of its stock on Nasdaq.
OpGen announced a 1-for-10 reverse stock split effective May 20, 2024. The split aims to increase the market price per share to meet Nasdaq's $1.00 minimum bid price requirement. The company's common stock will trade under the symbol 'OPGN' with a new CUSIP number, 68373L505. The split will reduce the number of outstanding shares from approximately 12.6 million to about 1.26 million. All stockholders will be affected proportionally, and fractional shares will be rounded up. Pacific Stock Transfer Company will manage the exchange of shares.
OpGen, Inc. announced the sale of its commercial customer contracts and Unyvero systems to Camtech Pte for $218,000. Additionally, Ares Genetics GmbH sold its assets to bioMerieux S.A. OpGen plans to work with Camtech and Curetis team to transfer U.S. Unyvero customers. OpGen also offered Camtech the opportunity to acquire its remaining inventory for $176,000. OpGen's CEO sees these transactions as preparation for potential strategic transactions like a reverse merger.
